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Abstract
Juvenile Nasopharyngeal Angiofibroma (JNA) remains one of the most enig-
matic tumors encountered by laryngotologists-head neck surgeons. Its origin at a
particular age in a particular sex has intrigued many. Histopathologically benign,
JNAs are locally aggressive tumors with tendency to cause massive recurrent nasal
bleeds. While surgery remains the gold standard treatment, a paradigm shift from
open approaches to endoscopic approach is noted. Recent advances in genomic
testing, radiodiagnosis and endoscopic nasal surgeries allow us to manage these
tumors more efficiently. Introduction of intensity modulated radiotherapy (IMRT),
stereotactic surgery, and interventional radiology (embolisation) has further helped
in this cause. This chapter aims to give a brief overview of all these aspects related to
JNA with the hope to initiate more ENT surgeons to contribute to further research
on this benign but dangerous tumor.
Keywords: juvenile nasal angiofibroma, JNA, vascular tumor, epistaxis,
pterygopalatine fossa, frog face deformity, pathways of spread of angiofibroma,
staging of JNA, immunohistochemistry of JNA, open surgery for angiofibroma,
endoscopic resection, treatment of angiofibroma, embolisation, CT angiography
1. Introduction
Juvenile nasopharyngeal angiofibroma (JNA) is a benign, non-encapsulated,
highly vascular tumor, occurring almost exclusively in adolescent males. Although
JNAs comprise of less than 0.05% of all head and neck tumors, their tendency to
bleed torrentially makes them an interesting disease entity to study and treat [1].
Development of other medical fields has been instrumental in studying the
origin, growth and other characteristics of this disease entity. Advancements in
radiology, histopathology and endoscopic nasal surgeries have been particularly
useful. We can now better diagnoses, stage and treat JNA than the previous decade.
2. History of juvenile nasopharyngeal angiofibroma
Earliest known documentation of juvenile nasopharyngeal angiofibroma is
credited to Hippocrates in the 4th century BC [2]. The term “juvenile nasopharyn-
geal angiofibroma” was coined by Chaveau in 1906 and his works re-sparked the
interest in JNA [3]. Shaheen et al. [4] reported the first female case of JNA (1930).
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Harma et al. in 1959 gave a detailed clinico-pathological insight into this tumor
[5]. Works of Bensch, Ewing, Som, Neffson, Moore, Handousa, Denker etc. have




Nasopharynx is a near-cuboidal shaped space with an approximate volume of
30cm3. It is located exactly below the middle cranial fossa.
Boundaries of Nasopharynx:
• Anterior: Choanae and posterior margin of nasal septum. Further anteriorly lie
the right and left nasal cavities.
• Posterior: Fascia, prevertebral muscles, basiocciput and first two cervical
vertebrae.
• Superior: Superior wall is continuous with the posterior wall. It is formed by
basisphenoid and basiocciput.
• Inferior: Opens into oropharynx. When the soft palate is elevated, it makes
contact with the Passavant’s ridge (palatopharyngeus muscle fibers); and
together these from the inferior boundary of nasopharynx.
• Lateral: Eustachian tube openings along with the torus tuboris is the
prominent structure.
Posterior to the torus tuboris, lies a deep recess called lateral pharyngeal recess
or fossa of rosenmuller. Foramen lacerum lies immediately superior to the fossa of
rosenmuller. Foramen spinosum and ovale are present laterally. Petrous apex and
carotid canal form its posterior relation (Figure 1).
Figure 1.
Endoscopic anatomy of nasopharynx as seen through right nasal cavity (E.T.- Eustachian Tube).
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3.2 Pterygopalatine fossa
Pterygopalatine fossa is a bilateral wedge-shaped space located below the orbital
apex and behind the posterior wall of maxillary sinus. It communicates with other
regions of skull through various canals and foramina.
Boundaries of Pterygopalatine Fossa:
• Anterior: Superomedial part of posterior wall of maxillary sinus.
• Posterior:Root of pterygoid process and anterior face of greaterwing of sphenoid.
• Medial: Upper part of perpendicular plate of palatine bone with its sphenoidal
and orbital process; sphenopalatine foramen leading to nasopharynx.
• Lateral: pterygomaxillary fissure leading to infratemporal fossa.
• Superior: Undersurface of body of sphenoid.
• Inferior: Pyramidal process of palatine bone with greater palatine canal.
Communications of Pterygopalatine Fossa:
• Via sphenopalatine foramen to nasopharynx
• Via pterygomaxillary fissure to infratemporal fossa
• Via inferior orbital fissure to orbit
• Via greater palatine canal to oral cavity
• Via foramen rotundum to middle cranial fossa
• Via vidian (pterygoid) canal to foramen lacerum to middle cranial fossa
• Via palatovaginal canal to pharynx
Contents of Pterygopalatine Fossa:
• Pterygopalatine ganglion with its branches
• Maxillary nerve (V2) and its branches
• Vidian Nerve (carrying secretomotor fibers of facial nerve from superior
salivatory nucleus and sympathetic fibers from internal carotid artery via deep
petrosal nerve)
• Third part of maxillary artery
4. Etiopathogenesis
Juvenile Nasopharyngeal Angiofibroma occurs almost exclusively in males and




19 years) [10]. Isolated cases of JNAs in females or in younger/ older ages have been
reported in literature [4, 11]. Exact etiology, although unknown, evidences point
towards a hormonal influence on its occurrence and growth.
4.1 Theories of origin
1.Ringertz Theory (1938): JNA arises from the periosteum of the skull
base [12].
2.Som- Neffson Theory (1940): If bones forming the skull base grow in a
disproportionate manner, it results in the hypertrophy of underlying
periosteum. Additional stimulation by hormones can result in formation of a
tumor in nasopharynx [6].
3.Bensch- Ewing Theory (1941): Between the basi sphenoid and basi occiput,
exists an embryonic fibrocartilage. This embryonic fibrocartilage proliferates
to form a tumor [7].
4.Brunner’s Theory (1942): JNA arises from conjoined buccopharyngeal and
pharyngobasilar fascia [13].
5.Martin’s Theory (1948): Imbalance between estrogens and
androgens during adolescence causes JNA. Increased estrogen stimulation
and/ or decreased androgen stimulation is suggested as the probable
cause [14].
6.Sternberg’s Theory (1954): JNAs are nothing but hemangiomas of nasal
cavity and skull base [15].
7.Handousa’s Theory (1954): JNA is a true neoplasm arising from periosteum
of basi sphenoid [9].
8.Osborn’s Theory (1959): Two theories were given by him. JNA is a fetal
erectile tissue which proliferates under hormonal influence (Pseudo-tumor
theory). Or, JNA is a true hamartoma (True tumor theory) [16].
9.Girgis- Fahmy’s Theory (1973): Histopathological resemblance between
JNA and paragangliomas was noted by Girgis and Fahmy. The growing edge
of JNA showed cell nests of undifferentiated epitheloid cells. They called this
pattern “Zellballen” (German- ball of cells). JNAs belong to the same disease
entity as paragangliomas [17].
10.Hamartoma and Vascular Malformation Theory: This is the most accepted
theory at present. Although, the dilemma still exists between JNA being a
hamartoma or a vascular malformation, influence of sex-hormones is an
accepted notion. While some consider JNAs to be true neoplasms, other
studies reveal these to be only vascular malformations [18–20].
11.Branchial Arch Artery Theory (Bernhard Schick, 2004): Incomplete
regression of first branchial arch artery has been proposed. First branchial
arch artery regresses near pterygoid base and sphenopalatine foramen, and is
finally incorporated into sphenopalatine and maxillary artery. This explains
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the anatomical location of the tumor at pterygoid base/ sphenopalatine
foramen as well as its supply by maxillary artery. This also explains the need
to drill pterygoid base to remove tumor remnants in this site of origin so as to
avoid tumor recurrence. As first branchial arch artery is connected to C4-
segment of internal carotid artery (ICA), its incomplete regression also
explains how JNAs acquire blood supply from ICA despite no anatomical
proximity [21].
4.2 Site of origin
Juvenile nasopharyngeal angiofibroma can arise from any one of the following
sites:
1.SPHENOPALATINE FORAMEN: Upper margin of the sphenopalatine is
considered as the most common site of origin of JNA. Sphenopalatine foramen
is the point of trifurcation of 3 bones: palatine (perpendicular plate, orbital
process and sphenoidal process), vomer (horizontal ala) and sphenoid
(specifically root of pterygoid process).
2.VIDIAN CANAL: Vidian canal/ pterygoid canal arises from the anterior wall
of foramen lacerum and opens into the posterior wall of pterygopalatine fossa.
Literature states this as potential site of origin in cases with laterally extended
JNAs having little/ no involvement of sphenopalatine foramen/ nasopharynx.
3.PTERYGOID WEDGE: Pterygoid wedge is found to be the most common site
of recurrence [22]. Drilling of pterygoid wedge during primary surgery
significantly reduces the risk of recurrence. First branchial arch artery theory
for origin of JNA supports the same. Recent studies have been conclusively
able to prove the same.
4.3 Factors for etiopathogenesis
Scientists are still looking out for exact etiological factors and how these affect
the growth of the tumor. Following factors should be considered:
1.Hormones: Occurrence of tumor in males during adolescence phase
strongly indicates hormonal influence on tumor growth initiation. An
imbalance between testosterone, estrogen and progesterone has been
theorized as an etiological factor. This allows the use of flutamide therapy as an
adjuvant therapy for its treatment. Flutamide has been found to be effective in
postpubertal patients as opposed to prepubertal patients [23].
2.Genetic alterations: gains and losses in the regions of 4q, 6q, 8q, 12, 17, 22q, X
and Y –chromosomes are present in patients of juvenile nasopharyngeal
angiofibroma [19, 24–26]. Over expression or under expression of p53 on
chromosome 17 has been implicated in tumor cells [27–30]. Her-2/neu
receptors (encoded by Her-2 gene on chromosome 17) have also a role in
JNA [29].
3.Molecular pathology: Cytokines such as transforming growth factor beta-1
(TGFβ-1) and Insulin-like growth factor-2 (IGF2) are involved in the growth




growth factor (PDGF) have been implicated as most important factors for
neoangiogenesis [28, 30]. AURKB, FGF18, and SUPT16H can act as potential
molecular markers in JNA [31].
5. Pathology
MACROSCOPIC: On gross examination, the tumor appears as a polypoidal,
non-encapsulated, red to gray colored mass with spongy appearance. Mean size
is 4 cm.
MICROSCOPIC: The tumor has a fibrous stroma with abundant blood
vessels. The blood vessels are of variable sizes without any organized layout.
Elastin fibers in the blood vessels are typically absent while the muscle layer maybe
absent, focal (pad-like) or circumferential. This accounts for profuse bleeding in
these tumors as these blood vessels are unable to contract to achieve effective
hemostasis.
The fibrous stroma has varying amounts of fine and coarse collagen fibers.
Plump spindle, angular, or stellate-shaped cells are also seen. Rarely, mast cells may
be present. The nuclei of stromal cells generally lack any characteristic features;
although, multinucleated pleomorphic cells are not uncommon.
The vascular and fibrous elements vary in proportion within the same tumor and
with the tumor age. While the fibrous component is more towards the centre of the
tumor, peripheral areas have abundance of vascular elements. Also, newer lesions
have predominantly vascular component while long standing tumors are enriched
with fibrous tissue.
Embolised specimens show myxoid changes with areas of infarction.
Embolic agent can be seen in the tumor vessels. Post flutamide therapy or
radiotherapy specimens show a significant increase in fibrous component
(Figure 2).
IMMUNOHISTOCHEMISTRY: Immunohistochemistry (IHC) tests act as
ancillary tests for juvenile nasopharyngeal angiofibroma. Various IHC tests are
described in the Table 1.
Figure 2.
Histopathological section of JNA as seen under a microscope. Multiple blood vessels of varying diameters are seen
in a fibrous stroma.
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6. Spread of JNA
JNA arises at the upper lip of sphenopalatine foramen. As it grows further, it
spreads along the path of least resistance to involve many vital structures.
6.1 Medial extension
From sphenopalatine foramen, it extends into the nasopharynx and grows
submucosally. It can occupy the entire nasopharynx to produce bilateral nasal
obstruction and nasal intonation of voice (rhinolalia clausa). Recurrent epistaxis
often starts at this stage only. The tumor mass may depress the soft palate or hang in
the oropharynx. Blockage of eustachian tube(s) results in conductive hearing loss
(otitis media with effusion).
6.2 Anterior extension
i. It enters the ipsilateral nasal cavity first to cause unilateral nasal obstruction
and epistaxis. Here it may acquire secondary attachments.
ii. As the tumor grows further within the ipsilateral nasal cavity, it pushes the
nasal septum towards the opposite side to produce contralateral nasal
obstruction as well.
iii. Further tumor growth allows it to involve ethmoidal sinuses. This results in






1.Vimentin Vascular & Fibrous All tumor cells Cytoplasmic
2.Androgen
receptor
Vascular & Fibrous All stromal cells and endothelial cells Nuclear
3.VEGF Vascular & Fibrous Stromal and vascular cells Cytoplasmic
4.PDGF Vascular & Fibrous Stromal and vascular cells (+/) Cytoplasmic
5. IGF-2 Vascular & Fibrous Stromal and vascular cells (+/) Cytoplasmic
6.TGF- β Vascular & Fibrous Stromal and vascular cells (+/) Cytoplasmic
7. SMA (Smooth
Muscle Actin)
Vascular Smooth muscle cells in blood vessels Cytoplasmic
8.Desmin Vascular Cells in walls of larger blood vessels Cytoplasmic
9.FVIIIRAg Vascular Endothelial cells Cytoplasmic
10.CD31 Vascular Endothelial cells Cytoplasmic
11.CD34 Vascular Endothelial cells Cytoplasmic
12.ER Vascular Vascular cell nuclei (+/) Nuclear
13.PR Vascular Vascular cell nuclei (+/) Nuclear
14.CD117 (c-kit) Fibrous Stromal cells Cytoplasmic
15.β Catenin Fibrous Stromal cells Nuclear
Table 1.




An associated proptosis gives a classical ‘frog- face deformity’ to the
patient.
iv. The tumor may encroach upon and erode anterior wall of sphenoid sinus. It
may further invade the sphenoid sinus.
6.3 Lateral extension
Lateral growth of the tumor results in the involvement of pterygopalatine fossa.
Pterygopalatine fossa is a small wedge-shaped cavity, which can be considered as a
cross-section/ junction point of many important ‘highways’.
i. As the mass lesion fills the pterygopalatine fossa, it causes anterior bowing
of the posterior wall of maxillary sinus (Antral Sign/ Holman- Miller
Sign).
ii. From pterygopalatine fossa, it can extend into the orbit via the inferior
orbital fissure. This produces proptosis. Further involvement of orbital
apex results in loss of vision. Involvement of extraocular muscles produces
diplopia.
iii. From pterygopalatine fossa, tumor grows laterally to invade infratemporal
fossa via the pterygomaxillary fissure. This causes facial swelling and
fullness in the cheek region. Erosion of the anterior face of greater wing of
sphenoid causes entry of tumor into the middle cranial fossa.
iv. From pterygopalatine fossa, it can grow along the vidian canal to reach
foramen lacerum. Foramen lacerum opens in the middle cranial fossa,
providing easy access to the tumor for intra cranial extension.
6.4 Posterior extension
i. The tumor can erode the pterygoid process posteriorly and spread
downwards into the pterygoid fossa. It can reach as far as the
parapharyngeal space.
ii. Tumor growth in the posterolateral part of nasopharynx can cause
extension into the fossa of rosenmuller. Further posterolateral growth into
the apex of this fossa results in intracranial extension by eroding the carotid
canal and petrous apex.
6.5 Inraorbital extension
The tumor can involve the orbit through the following routes-
i. Sphenopalatine foramen ➔ pterygopalatine fossa ➔ via inferior orbital
fissure ➔ enters orbit.
ii. Sphenopalatine foramen ➔ nasopharynx and nasal cavity ➔ erodes
lamina papyracea ➔ enters orbit.
6.6 Intracranial extension
The tumor can have intracranial extension through the following routes:
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i. Sphenopalatine foramen ➔ pterygopalatine fossa ➔ infratemporal fossa
➔ erosion of anterior face of greater wing of sphenoid AND/ OR through
foramen ovale causing its widening ➔ middle cranial fossa. The tumor lies
lateral to Internal Carotid Artery (ICA) and Cavernous Sinus (CS) in such
cases.
ii. Sphenopalatine foramen ➔ pterygopalatine fossa ➔ via inferior orbital
fissure ➔ orbit ➔ growth within orbit towards orbital apex and superior
orbital fissure ➔ middle cranial fossa. The tumor lies anterolateral to ICA
and lateral to CS.
iii. Sphenopalatine foramen ➔ nasopharynx and nasal cavity ➔ erosion of
floor and anterior wall of sphenoid sinus to invade sphenoid sinus ➔
erosion of roof of sphenoid sinus ➔ intracranial spread. The tumor lies
medial to ICA and lateral to pituitary gland.
iv. Sphenopalatine foramen ➔ pterygopalatine fossa ➔ pterygoid (vidian)
canal ➔ foramen lacerum ➔ middle cranial fossa. Encasement of ICA is
seen early.
v. Sphenopalatine foramen ➔ nasopharynx ➔ fossa of rosenmuller ➔
erodes carotid canal and petrous apex ➔ intracranial spread.
vi. Sphenopalatine foramen ➔ nasopharynx ➔ nasal cavity ➔ through




The patient is almost invariably male in his second decade of life. Mean age of
presentation is 14 years (reference).
7.2 Symptoms
The patient may have one or more of the following symptoms
i. Nasal bleed: any adolescent male presenting with recurrent nasal bleeds
should always raise the suspicion of angiofibroma. Nasal bleeds are usually
massive and often require an intervention to control them.
ii. Nasal obstruction: initially unilateral. Later, bilateral nasal obstruction
develops owing to involvement of entire nasopharynx or pushing of nasal
septum to the other side
iii. Nasal discharge: mucopurulent nasal discharge due to pent up secretions in
the nasal cavity followed by secondary infection.
iv. Hyposmia/ Anosmia: mechanical obstruction due to tumor mass of olfactory




v. Weakness and irritability: easy fatiguability and irritability due to frequent
nasal bleeds causing chronic anemia.
vi. Voice change: Voice takes a nasal intonation owing to the tumor mass in the
nasopharynx (rhinolalia clausa). Tumor mass depressing the soft palate
causes ‘plummy voice’.
vii. Facial swelling: ipsilateral cheek swelling results when JNA involves the
infratemporal fossa.
viii. Facial deformity: flattening of dorsum of nose with increased intercanthal
distance and proptosis results in ‘frog face deformity’.
ix. Headache: headache may result from chronic rhinosinusitis, or chronic
anemia, or intracranial extension of tumor.
x. Otological/ Aural symptoms: eustachian tube blockade in nasopharynx
results in serous otitis media causing conductive hearing loss and heaviness
in ears.
xi. Ocular symptoms: involvement of orbit causes proptosis, double vision, or
even loss of vision.
xii. Intracranial symptoms: headache, seizures, loss of consciousness owing to
intracranial spread of tumor.
7.3 Anterior rhinoscopy
Mucopurulent discharge in the involved side is seen. Tumor mass may also be
visualized. Septum is often deviated towards contralateral side.
7.4 Posterior rhinoscopy
Mass lesion is visualized in the nasopharynx.
7.5 Diagnostic nasal endoscopy
Examination with a Hopkin’s rigid rod lens 0o endoscope reveals a fleshy mass
lesion. It is usually covered in mucopurulent secretions which require gentle
suctioning. Probing is avoided as it can complicate into profuse nasal bleed.
8. Investigations
8.1 Biopsy
Though for any nasal mass, golden rule is that biopsy is preceded by
radiological imaging to ascertain origin, extent, and nature of the disease; in
vascular tumors such as JNAs, biopsy is contraindicated. Risk of bleeding during
and/ or after the procedure outweighs any added advantage we may get out of
preoperative biopsy.
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8.2 X-ray PNS
Water’s view (Occipitomental view)/ Peer’s view (Occipitomental view with
open mouth) shows haziness of the involved sinus. Lateral view shows anterior
bowing of posterior wall of maxillary antrum (Holman Miller sign).
8.3 CT NOSE–PNS
Contrast enhanced computed tomographic imaging is the investigation of choice
for JNA. Infact, the diagnosis of JNA is confirmed by presence of a mass in nasophar-
ynx and pterygopalatine fossa that enhances after contrast administration on CECT.
CECT is a non-invasive procedure that forms the basis for JNA diagnosis and staging.
Lloyd’s criteria for diagnosis of JNA on CECT [32]:
i. mass lesion in the nasopharynx/ nasal cavity and pterygopalatine fossa
ii. erosion of posterior bony margin of sphenopalatine foramen with extension
to the upper medial pterygoid plate.
Holman Miller sign/ Antral sign: anterior bowing of the posterior wall of maxillary
antrum. This is due to the tumor mass completely filling the pterygopalatine fossa.
Hondousa Sign: widening of the gap between the maxillary body and ramus of
mandible. This occurs when the tumor mass involves infratemporal fossa.
Ram Haran Sign: In JNA patients, coronal cuts of CT Nose- PNS show widening
of the pterygoid wedge. It appears as a quadrilateral area rather than normal trian-
gular area [33].
Chopstick Sign: CECT when used for post-operative surveillance to detect resid-
ual/ recurrent tumor, shows ‘floating’ medial and lateral pterygoid plates in cases
where the root of pterygoid base is drilled. These pterygoid plates are visualized
separately to give appearance of a pair of chopsticks.
8.4 MRI
Contrast enhanced MRI (CE-MRI) is the investigation of choice for advanced
JNA tumors, particularly those with intracranial, intra-orbital, or parapharyngeal
space involvement. It can accurately determine the extent of the tumor. ‘Salt and
pepper’ appearance on contrast MRI is characteristic to any vascular tumor,
resulting due to flow-void areas (T2WI and contrast enhanced T1WI) [22, 34].
Fat Suppression MRI: This has an immense potential in detecting bone invasion
by tumor. In fat-suppression MRI sequence, a normal pterygoid wedge should be
hypointense owing to fat-rich marrow. Any iso/hyper-intensity in that area indi-
cates invasion by the tumor, therefore, requiring bone drilling to avoid recurrence.
MRI is also the preferredmodality for post-operative long-term surveillance because
of its superior soft tissue differentiation quality without any radiation exposure.
8.5 CT-angiography
CT angiography is useful to identify the feeder vessel(s) to the tumor. Internal
maxillary artery is the most common feeder vessel for JNA. JNA may additionally
acquire blood supply from ascending pharyngeal artery, contralateral external
carotid artery branches, ipsilateral or contralateral internal carotid artery and its




Knowledge about the feeding vessel and its site of entry into the tumor is
absolutely critical to decide the surgical approach for JNA excision. For example,
where feeder vessels are located posterior to the main tumor mass without direct
access, open approach is preferred to endoscopic approach.
8.6 Digital subtraction angiography (DSA)
DSA is used in preoperative phase to identify the feeder vessel and its preoper-
ative embolization. Selective vessel angiography in DSA allows to determine the
exact branch(es) supplying the tumor and its selective embolization. JNA shows a
characteristic ‘tumor blush’ in DSA of external carotid artery. This can also help in
predicting the expected blood loss during tumor resection [35].
9. Staging of JNA
Various staging systems have been proposed over the years, each with its own
merits and demerits.
9.1 Session’s staging system, 1981
Table 2




I Involvement of the nasopharyngeal vault
II Extension into nasal cavity or sphenoid sinus




JNA staging system by Chandler, 1984 [37].
SESSION’S STAGING SYSTEM
STAGE TUMOR EXTENSION
IA Involvement of the nose or nasopharyngeal vault
IB Extension into one or more sinuses
IIA Minimal extension into the pterygopalatine fossa
IIB Full occupation of the pterygopalatine fossa
IIC Infratemporal extension ( involvement of the cheek)
III Intracranial extension
Table 2.
JNA staging system by Sessions, 1981 [36].
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9.3 Andrews-Fisch’s staging system, 1989
Table 4




IA Involvement of the nose or nasopharyngeal vault
IB Extension into one or more sinuses
IIA Minimal extension into pterygopalatine fossa
IIB Complete extension into pterygopalatine fossa
IIC Extension into infratemporal fossa/ posterior to pterygoid plates
IIIA Minimal skull base involvement (middle cranial fossa/ base of pterygoid plates)
IIIB Extensive intracranial involvement  involvement of cavernous sinus
Table 5.
JNA staging system by radkowski, 1996 [39].
9.5 Endoscopic system of staging
9.5.1 UPMC (University of Pittsburgh Medical Center)/ Snyderman, 2010
Only valid for tumors which are preoperatively embolised (Table 6).
ANDREWS-FISCH’S STAGING SYSTEM
STAGE TUMOR EXTENSION
I Confined to nose or nasopharyngeal vault
II Invasion of the pterygopalatine fossa or maxillary/ ethmoid/ sphenoid sinuses with bone
destruction
IIIA Extension into the infra- temporal fossa or orbit
IIIB Intracranial but extradural extension (parasellar area)
IVA Intracranial intradural extension without involving cavernous sinus/ optic chiasma/
pituitary fossa (mnemonic C-O-P)
IVB Intracranial intradural extension involving cavernous sinus/ optic chiasma/ pituitary fossa
Table 4.
JNA staging system by Andrew- Fisch, 1989 [38].
UPMC/ SNYDERMAN’S STAGING SYSTEM
STAGE TUMOR EXTENSION
I Nasal cavity, medial pterygopalatine fossa
II Paranasal sinuses and lateral pterygopalatine fossa, no residual vascularity





Choice of treatment depends on the size and extent of the tumor. Treatment
modalities include surgical excision (open v/s endoscopic approach) and non-
surgical adjuvant therapy (embolization/hormonal/ radiotherapy) or their
combination(s).
10.1 Surgical treatment of JNA
Complete excision of the entire tumor mass should be the aim of any surgical
procedure and the approach selected accordingly. Though the advancements in
endoscopic surgery have minimized the need for open approaches, the surgeon
should be well versed with all the techniques.
10.1.1 Open surgical approach
In general, open approaches have the advantage of providing a wide exposure.
But this comes at the cost of higher morbidity, increased hospital stay, and some
degree of cosmetic deformity.
10.1.1.1 Transpalatal approach [41, 42]
This is the shortest and most direct approach for tumors limited to nasopharynx
with/ without minimal extension into sphenoid sinus/ choana.
A U-shaped incision (Wilson’s incision) is made 2.5 cm anterior to the junction
of hard and soft palate. Submucoperiosteal flap is elevated posteriorly till the soft
palate to bare the underlying horizontal plate of palatine bone. Soft palate and hard
palate are separated. Bone is removed from the posterior part of hard palate to
visualize the entire nasopharynx along with the tumor.
This approach has the advantage of good post-operative healing with no
visible scar.
10.1.1.2 Transnasal- maxillary approach
10.1.1.2.1 Lateral rhinotomy
Lateral rhinotomy was first described by Irwin Moore in 1917 [43].
The incision is started 5 mm anterior and superior to the medial canthus and
continued inferiorly along the deepest portion of the nasomaxillary groove. At its
inferior end, it is curved medially in the crease beneath the ala. Skin flaps are
UPMC/ SNYDERMAN’S STAGING SYSTEM
STAGE TUMOR EXTENSION
IV Skull base erosion, orbit, infratemporal fossa, with residual vascularity from ICA
V Intracranial extension with residual vascularity from ICA
VM Medial cavernous sinus
VL Middle cranial fossa
Table 6.
JNA staging system by Snyderman/ UPMC, 2010 [40].
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elevated over the maxilla and nasal bones. Medial wall of maxillary antrum is
removed.
This provides adequate exposure for tumors extending into the nasal cavity and/
or sinuses with minimal extension into the pterygopalatine fossa.
Adequate healing allows for an inconspicuous scar mark, well hidden within the
facial creases.
10.1.1.2.2 Extended lateral rhinotomy
The lateral rhinotomy incision is further extended inferiorly along the ipsilateral
ridge of the philtrum and continued to split the upper lip in paramedian position.
After dividing the upper lip, incision is continued laterally along the gingivobuccal
sulcus upto the first molar. This approach is required in cases needing exposure
beyond the infraorbital neurovascular bundle.
10.1.1.2.3 Extended subtoal maxillectomy
The main objective of this approach is to expose the maxillary antrum and
remove its medial, anterior and posterolateral walls along with perpendicular plate
of palatine bone. Orbital floor and alveolar arch are left intact. This converts the
maxillary sinus, nasal cavity, nasopharynx, pterygopalatine fossa and infratemporal
fossa into a single large accessible cavity.
This wide exposure is required for large tumors spilling in the infratemporal
fossa. Lateral most aspect of these tumors is identified. Feeder vessel in the form of
internal maxillary artery (most common feeder vessel) is identified as it enters the
lateral aspect of the tumor in the infratemporal fossa and ligated before starting
with the tumor dissection. Ascending pharyngeal artery maybe seen entering and
supplying the tumor at its posterior aspect. It is also identified and ligated. This
allows for minimal blood loss during the tumor dissection and delivery. Tumor
delivery is done in-toto through transnasal/ transoral route or in a piecemeal
fashion.
Two pathways for this approach have been described:
I.Weber-Ferguson’s Incision: The incision starts just below the lateral canthus
upto the medial canthus in the subciliary crease. It is continued inferiorly
along the nasomaxillary groove and turned medially at alar crease. It is again
curved inferiorly along the philtrum to split the upper lip. Gingivobuccal
incision is extended laterally upto the first molar area. Ectropion, cheek
anesthesia, and an unsightly scar are often encountered complications of this
approach.
II.Mid Facial Degloving: A complete transfixation incision is placed in the
anterior nasal septum followed by bilateral intercartilagenous incisions
between upper and lower lateral cartilages. Incision over the pyriform
aperture is made on both sides. A sublabial incision between the two upper
second molars is made and dissection continued superiorly to join it with the
nasal incisions. Entire skin and soft tissue flap is retracted superiorly to reveal
the whole midface skeleton. Although more technologically challenging, this
approach has the advantage of no visible scar. Cheek anesthesia is an almost
inevitable complication. Nasal vestibular stenosis has also been reported with




10.1.1.2.4 Le fort-I approach
An incision is made in the gingivobuccal sulcus between the two upper second
molars. Periosteum is elevated to expose maxilla in its anterior and lateral aspect.
Horizontal osteotomies from pyriform aperture to pterygomaxillary fissure and
from pyriform aperture to palatine canals are made. Nasal septum is freed from
anterior nasal spine and maxillary crest. Pterygoid dysjuctioning allows easy
down fracturing of maxilla to achieve a wide exposure of the tumor extending
into multiple paranasal sinuses, infratemporal fossa or intracranial space.
After tumor excision, fixation of mid facial skeleton is achieved using titanium




A Weber-Ferguson incision is combined with the splitting of the hard palate
[45, 46]. Multiple osteotomies are done and maxilla is disarticulated. Overlying skin
and muscles are NOT dissected. Rather they are raised as a single flap along with
underlying maxillary and zygomatic bone (cheek masseter maxillary flap). After
tumor excision, maxilla is repositioned and fixed with titanium plates followed by
layered suturing of the skin incision.
This approach provides accessibility to nasopharynx, paranasal sinuses,
infratemporal fossa, parapharyngeal space and intracranial space. Malocclusion of
upper jaw and palatal fistula are some uncommon but difficult to manage compli-
cations associated with this procedure [47].
10.1.1.3.2 Maxillary removal and reinsertion (MRR)
MRR starts as a midfacial degloving approach through a sublabial incision [48].
Partial osteotomy at nasofrontal angle allows extended degloving of midface. Mul-
tiple osteotomies are made to resect and remove the maxillary bone. Tumor is
resected. Maxilla is repositioned at its original anatomical position and secured with
titanium plates/ absorbable plates.
Wide exposure for tumor resection from infratemporal fossa, parapharyngeal
space, and middle and anterior cranial fossa is achieved. Such extensive resections
can cause malocclusions, visual disturbances and disruption of growth centres in
the maxillary bone, resulting in future cosmetic deformities.
10.1.1.4 Infratemporal fossa approach
Fisch Type C and Fisch Type D are the two most commonly used approaches
for extensive JNAs. Infratemporal approaches are suitable for gaining excess to
infratemporal fossa, middle cranial fossa and lateral cavernous sinus [49]. Good
resection rates are achieved with low recurrence rates. Major complications of
Fisch Type C approach are a permanent conductive hearing loss, cosmetic defor-
mity and loss of facial sensation. Fisch Type D approach was later added with the
advantage of avoiding a visible facial scar, hearing loss and ability to convert as
Type C approach as and when required [50, 51]. However, these approaches fail
to resect tumors extending medial to the abducent cranial nerve in the cavernous
sinus [52].
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10.1.1.5 Craniofacial resection
A combination of infratemporal fossa approach and transfacial approach is
required in certain cases with advanced stage angiofibromas [52]. This approach
allows access to the infratemporal fossa, middle and anterior cranial fossa, and
entire cavernous sinus (both medial and lateral aspects). An added enhanced expo-
sure to the nasopharynx, paranasal sinuses and pterygopalatine fossa facilitates
complete tumor excision. Facial skeletal growth retardations and facial asymmetry
is rare [53].
10.1.1.6 Combined open approach
Large primary tumors or recurrent tumors may necessitate the need for using more
than one open approach in the same sitting. These combinations can be tailor –made
depending on size of the tumor, involvement of vital structures, and surgeon’s exper-
tise in one or more approaches. Some commonly used combined approaches are-
i. Transapalatal + Lateral Rhinotomy: In large tumors, not amenable to
single approach surgery, this was the most common approach used earlier.
ii. Sardana’s Approach: Sublabial approach combined with a partial transpalatal
approach (without removing bone from posterior part of hard palate) [54].
iii. Midface Degloving + Transzygomatic Approach: This achieves a wide
exposure with radical tumor excision and good hemostasis [55].
iv. Triple Approach of Hiranandani: Combination of lateral rhinotomy with
transpalatal approach with Caldwell-Luc’s approach [56].
v. Craniofacial Resections: Infratemporal fossa approach combined with
transfacial approach. Craniofacial resections can be included in this
category as well [52].
10.1.2 Endoscopic approach
Last decade has seen a paradigm shift from open approach to transnasal endo-
scopic approach. In today’s time, endoscopic surgery can be regarded as the most
rapidly advancing surgical field. As the surgeon’s familiarity with the endoscopes is
increasing, hard to reach anatomical regions are also becoming more accessible,
thereby, widening the horizon for this approach. Tumors, which were earlier
labeled as operable via an open approach only, can now be easily and completely
resected using endoscopic approach.
Endoscopic surgery has the advantage of better illumination andmagnification,
lowermorbidity, and shorter duration of hospital stay which ultimately leads to cost
saving. Advantage of no visible facial scar adds to the cosmetic viability of this approach.
10.1.2.1 Surgical considerations for endoscopic jna surgery
1.Tumor size and extent decides the exact endoscopic approach required. While
smaller tumors are managed via an endonasal approach; medium to large sized
tumors require an endoscopic Denker’s / Sturman- Canfield or a more




Extended anterior skull base approaches are recommended for intracranial
lesions [59].
1.Exposure is the key to a successful surgery. Adequate exposure allows
identification of tumor limits, delineation of feeder vessels, and assessment of
tumor’s relation with vital structures. Most of the surgical time is spent in
achieving this exposure before starting off with the tumor resection.
2. It is always advisable to identify and ligate the feeding artery first (usually
internal maxillary artery), before starting with tumor dissection.
3.Posterior septectomy, wherever required, is recommended. This greatly
increases the access to the tumor.
4.Dissection is carried along the tumor pseudocapsule from lateral to medial
direction. Any injury to tumor surface can provoke massive bleeding.
5.For larger tumors, a four-handed technique is recommended [22]. For large
tumors with extensive lateral extension into infratemporal fossa/
parapharyngeal space, the four-port Bradoo’s technique is a worthy option [60].
6.Drilling of pterygoid base at the end of the procedure should be a routine
practice, so as to minimize the recurrence rates (Figures 3–8).
7.The operative room should have the availability of hemostatic materials like
SURGICEL, FLOSEAL, TIS SEEL and a functioning bipolar cautery. Access to
a blood bank is recommended.
8.Coblation is a plasma based device that can be used for surface coagulation of
the tumor without causing any collateral thermal damage. This shrinks the
tumor and also greatly reduces intra-op bleeding.
9.During preoperative planning stage, it is imperative to discuss with the
patient, the possibility to convert an endoscopic approach into an open
approach at any given time during the surgery.
Figure 3.
CE-MRI showing hyperintense tumor (*) with massive lateral extension into infratemporal fossa.
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10.1.2.2 Contraindications to endoscopic approach
i. Broad skull base infiltration
ii. extensive blood supply from ICA
iii. encasement of ICA
iv. brain infiltration
Considering the pace of progress in endoscopic techniques, it would not be sur-
prising if somemore indications are added by the time this chapter reaches the readers.
Figure 4.
CE-MRI showing hyperintense tumor (*) in the infratemporal fossa.
Figure 5.
CECT showing JNA occupying nasopharynx (1), pterygoid wedge (2), infratemporal fossa (3) and
intracranial space (4). Notice the widening of left pterygoid wedge (red arrow) as compared to the right normal




10.2 Non-surgical treatment of JNA: adjuvant treatment modalities
Though Juvenile angiofibroma is now an established surgical entity, there has
been an era when medical management alone was the rule for extensive tumors
especially those with intracranial extension. With paradigm shift towards more
aggressive surgical procedures for all stages of the tumor, other treatment
modalities are now valued as adjuvant therapy only.
10.2.1 Embolization
Transarterial embolization (TAE) is done preoperatively to decrease the blood
flow to the tumor, thereby, reducing the intraoperative blood loss and need for
blood transfusion. This is particularly useful for tumors with advanced stage.
Figure 6.
CT angiography showing a vascular tumor (*). Notice the internal maxillary artery supplying this tumor (orange
arrow).
Figure 7.
Endoscopic view through left nasal cavity: Medial and posterior walls of left maxillary sinus and left inferior
turbinate have been removed. 1-nasopharyngeal component of JNA; 2- pterygopalatine fossa + infratemporal
fossa component of JNA; 3- remnants of left inferior turbinate; R- right, L- left, S- superior, I- inferior.
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Smaller tumors have less vascularity and can be resected easily even without
preoperative embolization [61].
The procedure is usually done 24 to 48 hours before the scheduled surgery.
Further surgical delay is not appreciated/recommended as tumor gains collateral
blood supply through neoangiogenesis. A wide variety of materials are available as
embolic agents: microspheres, gelatin sponge, Teflon particles, gel foam, poly-vinyl
alcohol, polystyrene, silicone particles, silk, cyanoacrylate, sodium tetradacyl sul-
phate, autogenous clot, duramater, muscle fragments, etc. 300–500 micrometer
spheres are preferred owing to greater blocking capacity of vascular lumen [62].
The procedure is not without complications. Cerebral ischemia and vision loss are
known complications following embolic agent migrating to ICA system. Rare com-
plications like cerebral edema, hemiplegia and aphasia have also been reported [63].
Direct Puncture Therapeutic Embolization (DPTE) is a new concept for
tumor embolization. Embolizing agent is a mixture of n-butyl cyanoacrylate
[NBCA], lipiodol, powdered tungsten with/without absolute ethanol. Under fluo-
roscopic visualization, embolizing agent is injected directly into the tumor through
a percutaneous route or a transoral/ transnasal/transpalatal route [64].
This results in almost complete filling of tumor microvasculature with irreversible
occlusion of embolized vessels. Tumor gains a dark color (due to tungsten powder
with blue dye) which helps to better distinguish it from surrounding normal tissue.
Direct cytotoxicity of absolute ethanol has shown good therapeutic effects.
DPTE alone or in combination with TAE has shown to have better
devascularisation effects than TAE alone [65, 66].
10.2.2 Hormonal therapy
Hormonal influence on growth of JNA has been speculated since long. An inter-
play between estrogens and androgens has been associated with tumor proliferation
and its spontaneous involution. Various hormonal therapies are recommended
based on these concepts.
Figure 8.
Coblation wand being used in juvenile nasopharyngeal angiofibroma endoscopic surgery. 1- coblation wand, 2-




Estrogen therapy: exogenous estrogen has been tried traditionally with the aim
of decreasing tumor size and vascularity. Lack of conclusive therapeutic advantage,
feminizing side effects and propensity towards cardiovascular side effects have
rendered its place to be of historical significance only.
Anti-androgen therapy: Flutamide is a non-steroidal androgen receptor blocker
drug, primarily used in prostatic cancer. It binds with the androgen receptors,
thereby blocking the action of testosterone. Recently, it has been proven that the
response to flutamide therapy is much more pronounced in post-pubertal patients
as compared to pre-pubertal patients [23].
Flutamide therapy is recommended as a six week preoperative adjuvant therapy
for intracranial and intraorbital lesions, recurrent lesions and those with their blood
supply primarily from ICA.
10.2.3 Radiotherapy
Low dose radiotherapy is used for angiofibromas extending intracranially, not
amenable to primary surgery. Typically, total radiation dose of 3,500 cGy is given
over 3 weeks. A successful response in terms of decreased tumor size and vascular-
ity is seen over several months in 80% of the patients [67, 68]. Those showing no
response/incomplete response by 2 years post radiotherapy are deemed as failures
and taken up for salvage surgery.
There are numerous side effects to use of radiotherapy at a young age. Posterior
capsular opacities, glaucoma, optic nerve atrophy, xerostomia, hypopituitarism,
cerebral necrosis, osteoradionecrosis of mandible, skull base osteomyelitis, risk of
developing new head–neck tumors later in life, potential malignant transformation
of angiofibromas are few of the complications associated with the use of radiother-
apy in head and neck region.
Intensity Modulated Radiotherapy (IMRT) allows higher doses to be given to
the lesion without damaging adjoining normal tissues. Multiple beams from differ-
ent directions converge onto the tumor shape so that the target area has the highest
dose strength with relative sparing of surrounding vital structures.
Gamma Knife makes use of radiation beams from 201 sources, converging onto
a single point. This causes retardation of further tumor growth. Cyber Knife is a
type of stereotactic radiosurgery which uses a robotic arm to deliver radiations to a
point source. These are being applied in association with other treatment modalities
to achieve desired results in large angiofibromas [69, 70].
11. Conclusion
Juvenile nasopharyngeal angiofibroma, although an old disease entity, is still
fascinating medical experts all over the world. Although still largely unknown, with
advanced genetic and molecular studies, we have moved a step closer to find the
origin and etiology of this disease. At present, surgery is the mainstay of treatment
with endoscopic approach replacing the conventional open approach. Future con-
siderations can be focused on therapeutic embolisation, stereotactic radiotherapy
and targeted molecular therapy for a non-surgical cure.
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